nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—ABCB1—Vismodegib—skin cancer	0.0648	0.142	CbGbCtD
Risperidone—CYP3A4—Temozolomide—skin cancer	0.056	0.123	CbGbCtD
Risperidone—CYP3A4—Imiquimod—skin cancer	0.056	0.123	CbGbCtD
Risperidone—CYP2D6—Vemurafenib—skin cancer	0.0483	0.106	CbGbCtD
Risperidone—CYP3A4—Vismodegib—skin cancer	0.0388	0.0852	CbGbCtD
Risperidone—CYP3A7—Docetaxel—skin cancer	0.036	0.079	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.036	0.079	CbGbCtD
Risperidone—ABCB1—Dactinomycin—skin cancer	0.034	0.0747	CbGbCtD
Risperidone—CYP3A4—Vemurafenib—skin cancer	0.0307	0.0673	CbGbCtD
Risperidone—CYP3A5—Docetaxel—skin cancer	0.027	0.0593	CbGbCtD
Risperidone—ABCB1—Docetaxel—skin cancer	0.0176	0.0386	CbGbCtD
Risperidone—CYP3A4—Docetaxel—skin cancer	0.0105	0.0231	CbGbCtD
Risperidone—HRH1—nose—skin cancer	0.00616	0.0716	CbGeAlD
Risperidone—DRD1—nerve—skin cancer	0.00378	0.044	CbGeAlD
Risperidone—H1F0—hair follicle—skin cancer	0.00321	0.0373	CbGeAlD
Risperidone—HTR2A—hindlimb—skin cancer	0.00242	0.0282	CbGeAlD
Risperidone—HTR1B—blood vessel—skin cancer	0.00241	0.028	CbGeAlD
Risperidone—HTR7—nerve—skin cancer	0.00236	0.0275	CbGeAlD
Risperidone—HTR1D—blood vessel—skin cancer	0.00233	0.0271	CbGeAlD
Risperidone—DRD2—nerve—skin cancer	0.00223	0.026	CbGeAlD
Risperidone—H1F0—nipple—skin cancer	0.00217	0.0253	CbGeAlD
Risperidone—H1F0—neck—skin cancer	0.00215	0.025	CbGeAlD
Risperidone—HTR2A—appendage—skin cancer	0.00208	0.0242	CbGeAlD
Risperidone—HTR7—endothelium—skin cancer	0.00201	0.0234	CbGeAlD
Risperidone—HTR7—blood vessel—skin cancer	0.00186	0.0216	CbGeAlD
Risperidone—H1F0—connective tissue—skin cancer	0.00154	0.0179	CbGeAlD
Risperidone—HTR2A—nerve—skin cancer	0.00147	0.0171	CbGeAlD
Risperidone—H1F0—skin of body—skin cancer	0.00139	0.0162	CbGeAlD
Risperidone—HTR7—neck—skin cancer	0.00133	0.0154	CbGeAlD
Risperidone—H1F0—mammalian vulva—skin cancer	0.00127	0.0148	CbGeAlD
Risperidone—HTR2A—endothelium—skin cancer	0.00126	0.0146	CbGeAlD
Risperidone—DRD3—head—skin cancer	0.00125	0.0146	CbGeAlD
Risperidone—KCNH2—nipple—skin cancer	0.00125	0.0145	CbGeAlD
Risperidone—ADRA2C—nipple—skin cancer	0.00123	0.0143	CbGeAlD
Risperidone—HTR1D—connective tissue—skin cancer	0.00119	0.0139	CbGeAlD
Risperidone—HTR2A—blood vessel—skin cancer	0.00116	0.0135	CbGeAlD
Risperidone—H1F0—lymphoid tissue—skin cancer	0.00113	0.0131	CbGeAlD
Risperidone—H1F0—female reproductive system—skin cancer	0.00109	0.0126	CbGeAlD
Risperidone—HTR2B—skin of body—skin cancer	0.001	0.0117	CbGeAlD
Risperidone—HRH1—nipple—skin cancer	0.001	0.0117	CbGeAlD
Risperidone—ADRA2A—nipple—skin cancer	0.000984	0.0114	CbGeAlD
Risperidone—ADRA1B—head—skin cancer	0.000963	0.0112	CbGeAlD
Risperidone—HTR7—connective tissue—skin cancer	0.000952	0.0111	CbGeAlD
Risperidone—H1F0—head—skin cancer	0.000909	0.0106	CbGeAlD
Risperidone—HTR7—epithelium—skin cancer	0.000904	0.0105	CbGeAlD
Risperidone—DRD1—head—skin cancer	0.000897	0.0104	CbGeAlD
Risperidone—ADRA1A—epithelium—skin cancer	0.000871	0.0101	CbGeAlD
Risperidone—HTR1B—female reproductive system—skin cancer	0.00087	0.0101	CbGeAlD
Risperidone—HTR1D—female reproductive system—skin cancer	0.000843	0.0098	CbGeAlD
Risperidone—HTR2C—female reproductive system—skin cancer	0.000834	0.0097	CbGeAlD
Risperidone—HTR2A—neck—skin cancer	0.000828	0.00963	CbGeAlD
Risperidone—HTR2B—female reproductive system—skin cancer	0.000784	0.00911	CbGeAlD
Risperidone—ABCB1—blood vessel—skin cancer	0.000759	0.00882	CbGeAlD
Risperidone—HTR1B—head—skin cancer	0.000727	0.00845	CbGeAlD
Risperidone—ADRA2C—mammalian vulva—skin cancer	0.00072	0.00838	CbGeAlD
Risperidone—HRH1—connective tissue—skin cancer	0.000711	0.00826	CbGeAlD
Risperidone—HTR1D—head—skin cancer	0.000704	0.00819	CbGeAlD
Risperidone—ADRA2A—connective tissue—skin cancer	0.000698	0.00812	CbGeAlD
Risperidone—HTR2C—head—skin cancer	0.000697	0.00811	CbGeAlD
Risperidone—HRH1—epithelium—skin cancer	0.000675	0.00784	CbGeAlD
Risperidone—ADRA1A—lymphoid tissue—skin cancer	0.000671	0.0078	CbGeAlD
Risperidone—HTR7—female reproductive system—skin cancer	0.000671	0.0078	CbGeAlD
Risperidone—HTR2B—head—skin cancer	0.000655	0.00761	CbGeAlD
Risperidone—H1F0—lymph node—skin cancer	0.000636	0.0074	CbGeAlD
Risperidone—KCNH2—female reproductive system—skin cancer	0.000625	0.00727	CbGeAlD
Risperidone—HTR2A—connective tissue—skin cancer	0.000593	0.0069	CbGeAlD
Risperidone—HTR1A—head—skin cancer	0.000587	0.00682	CbGeAlD
Risperidone—HRH1—mammalian vulva—skin cancer	0.000585	0.0068	CbGeAlD
Risperidone—ADRA2A—mammalian vulva—skin cancer	0.000575	0.00668	CbGeAlD
Risperidone—HTR2A—epithelium—skin cancer	0.000563	0.00655	CbGeAlD
Risperidone—HTR7—head—skin cancer	0.000561	0.00652	CbGeAlD
Risperidone—ADRA1A—head—skin cancer	0.000541	0.00629	CbGeAlD
Risperidone—DRD2—head—skin cancer	0.00053	0.00616	CbGeAlD
Risperidone—KCNH2—head—skin cancer	0.000522	0.00607	CbGeAlD
Risperidone—ADRA2C—head—skin cancer	0.000515	0.00599	CbGeAlD
Risperidone—HRH1—female reproductive system—skin cancer	0.000501	0.00583	CbGeAlD
Risperidone—ADRA2A—female reproductive system—skin cancer	0.000492	0.00572	CbGeAlD
Risperidone—HTR2B—lymph node—skin cancer	0.000459	0.00533	CbGeAlD
Risperidone—HRH1—head—skin cancer	0.000419	0.00487	CbGeAlD
Risperidone—HTR2A—female reproductive system—skin cancer	0.000419	0.00487	CbGeAlD
Risperidone—ADRA2A—head—skin cancer	0.000411	0.00478	CbGeAlD
Risperidone—CYP3A4—female reproductive system—skin cancer	0.000387	0.00451	CbGeAlD
Risperidone—CYP2D6—female reproductive system—skin cancer	0.000381	0.00443	CbGeAlD
Risperidone—ABCB1—epithelium—skin cancer	0.000369	0.00429	CbGeAlD
Risperidone—KCNH2—lymph node—skin cancer	0.000366	0.00425	CbGeAlD
Risperidone—ADRA2C—lymph node—skin cancer	0.000361	0.0042	CbGeAlD
Risperidone—HTR2A—head—skin cancer	0.00035	0.00407	CbGeAlD
Risperidone—ABCB1—mammalian vulva—skin cancer	0.00032	0.00372	CbGeAlD
Risperidone—CYP2D6—head—skin cancer	0.000319	0.0037	CbGeAlD
Risperidone—HRH1—lymph node—skin cancer	0.000293	0.00341	CbGeAlD
Risperidone—ADRA2A—lymph node—skin cancer	0.000288	0.00335	CbGeAlD
Risperidone—ABCB1—lymphoid tissue—skin cancer	0.000284	0.00331	CbGeAlD
Risperidone—ABCB1—female reproductive system—skin cancer	0.000274	0.00319	CbGeAlD
Risperidone—Discomfort—Bleomycin—skin cancer	0.000234	0.000554	CcSEcCtD
Risperidone—Malaise—Dactinomycin—skin cancer	0.000234	0.000553	CcSEcCtD
Risperidone—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000233	0.000552	CcSEcCtD
Risperidone—Leukopenia—Dactinomycin—skin cancer	0.000232	0.000549	CcSEcCtD
Risperidone—Nasopharyngitis—Docetaxel—skin cancer	0.000232	0.000548	CcSEcCtD
Risperidone—Dysgeusia—Temozolomide—skin cancer	0.00023	0.000544	CcSEcCtD
Risperidone—ABCB1—head—skin cancer	0.000229	0.00266	CbGeAlD
Risperidone—Asthenia—Imiquimod—skin cancer	0.000229	0.000542	CcSEcCtD
Risperidone—Confusional state—Bleomycin—skin cancer	0.000229	0.000542	CcSEcCtD
Risperidone—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000228	0.000541	CcSEcCtD
Risperidone—Anaphylactic shock—Bleomycin—skin cancer	0.000227	0.000537	CcSEcCtD
Risperidone—Oedema—Bleomycin—skin cancer	0.000227	0.000537	CcSEcCtD
Risperidone—Back pain—Temozolomide—skin cancer	0.000227	0.000537	CcSEcCtD
Risperidone—Pruritus—Imiquimod—skin cancer	0.000226	0.000535	CcSEcCtD
Risperidone—Infection—Bleomycin—skin cancer	0.000225	0.000534	CcSEcCtD
Risperidone—Dysphagia—Docetaxel—skin cancer	0.000224	0.00053	CcSEcCtD
Risperidone—Nausea—Vemurafenib—skin cancer	0.000222	0.000527	CcSEcCtD
Risperidone—Thrombocytopenia—Bleomycin—skin cancer	0.000222	0.000526	CcSEcCtD
Risperidone—Arrhythmia—Fluorouracil—skin cancer	0.000222	0.000525	CcSEcCtD
Risperidone—Vision blurred—Temozolomide—skin cancer	0.000221	0.000523	CcSEcCtD
Risperidone—Myalgia—Dactinomycin—skin cancer	0.000221	0.000523	CcSEcCtD
Risperidone—Bronchospasm—Docetaxel—skin cancer	0.00022	0.000521	CcSEcCtD
Risperidone—Tremor—Temozolomide—skin cancer	0.00022	0.00052	CcSEcCtD
Risperidone—Alopecia—Fluorouracil—skin cancer	0.000219	0.000519	CcSEcCtD
Risperidone—Diarrhoea—Imiquimod—skin cancer	0.000218	0.000517	CcSEcCtD
Risperidone—Discomfort—Dactinomycin—skin cancer	0.000218	0.000516	CcSEcCtD
Risperidone—Angina pectoris—Docetaxel—skin cancer	0.000218	0.000516	CcSEcCtD
Risperidone—Ill-defined disorder—Temozolomide—skin cancer	0.000218	0.000515	CcSEcCtD
Risperidone—Anaemia—Temozolomide—skin cancer	0.000217	0.000513	CcSEcCtD
Risperidone—Anorexia—Bleomycin—skin cancer	0.000216	0.000512	CcSEcCtD
Risperidone—Erythema—Fluorouracil—skin cancer	0.000216	0.000511	CcSEcCtD
Risperidone—Agitation—Temozolomide—skin cancer	0.000215	0.00051	CcSEcCtD
Risperidone—Angioedema—Temozolomide—skin cancer	0.000214	0.000507	CcSEcCtD
Risperidone—Hypotension—Bleomycin—skin cancer	0.000212	0.000502	CcSEcCtD
Risperidone—Oedema—Dactinomycin—skin cancer	0.000212	0.000501	CcSEcCtD
Risperidone—Malaise—Temozolomide—skin cancer	0.000211	0.000501	CcSEcCtD
Risperidone—Dizziness—Imiquimod—skin cancer	0.000211	0.0005	CcSEcCtD
Risperidone—Vertigo—Temozolomide—skin cancer	0.000211	0.000499	CcSEcCtD
Risperidone—Infection—Dactinomycin—skin cancer	0.00021	0.000498	CcSEcCtD
Risperidone—Leukopenia—Temozolomide—skin cancer	0.00021	0.000497	CcSEcCtD
Risperidone—Neutropenia—Docetaxel—skin cancer	0.000209	0.000495	CcSEcCtD
Risperidone—Palpitations—Temozolomide—skin cancer	0.000207	0.000491	CcSEcCtD
Risperidone—Thrombocytopenia—Dactinomycin—skin cancer	0.000207	0.00049	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000207	0.000489	CcSEcCtD
Risperidone—Cough—Temozolomide—skin cancer	0.000205	0.000484	CcSEcCtD
Risperidone—Paraesthesia—Bleomycin—skin cancer	0.000204	0.000482	CcSEcCtD
Risperidone—Weight increased—Docetaxel—skin cancer	0.000204	0.000482	CcSEcCtD
Risperidone—Vision blurred—Fluorouracil—skin cancer	0.000204	0.000482	CcSEcCtD
Risperidone—Convulsion—Temozolomide—skin cancer	0.000203	0.000481	CcSEcCtD
Risperidone—Vomiting—Imiquimod—skin cancer	0.000203	0.000481	CcSEcCtD
Risperidone—Weight decreased—Docetaxel—skin cancer	0.000202	0.000479	CcSEcCtD
Risperidone—Hypertension—Temozolomide—skin cancer	0.000202	0.000479	CcSEcCtD
Risperidone—Dyspnoea—Bleomycin—skin cancer	0.000202	0.000479	CcSEcCtD
Risperidone—Anorexia—Dactinomycin—skin cancer	0.000202	0.000477	CcSEcCtD
Risperidone—Rash—Imiquimod—skin cancer	0.000201	0.000477	CcSEcCtD
Risperidone—Dermatitis—Imiquimod—skin cancer	0.000201	0.000476	CcSEcCtD
Risperidone—Pneumonia—Docetaxel—skin cancer	0.000201	0.000475	CcSEcCtD
Risperidone—Headache—Imiquimod—skin cancer	0.0002	0.000474	CcSEcCtD
Risperidone—Anaemia—Fluorouracil—skin cancer	0.0002	0.000473	CcSEcCtD
Risperidone—Myalgia—Temozolomide—skin cancer	0.0002	0.000473	CcSEcCtD
Risperidone—Arthralgia—Temozolomide—skin cancer	0.0002	0.000473	CcSEcCtD
Risperidone—Infestation NOS—Docetaxel—skin cancer	0.0002	0.000472	CcSEcCtD
Risperidone—Infestation—Docetaxel—skin cancer	0.0002	0.000472	CcSEcCtD
Risperidone—Anxiety—Temozolomide—skin cancer	0.000199	0.000471	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000198	0.000469	CcSEcCtD
Risperidone—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000198	0.000468	CcSEcCtD
Risperidone—Discomfort—Temozolomide—skin cancer	0.000197	0.000467	CcSEcCtD
Risperidone—Decreased appetite—Bleomycin—skin cancer	0.000197	0.000467	CcSEcCtD
Risperidone—Acute coronary syndrome—Docetaxel—skin cancer	0.000197	0.000466	CcSEcCtD
Risperidone—Renal failure—Docetaxel—skin cancer	0.000196	0.000464	CcSEcCtD
Risperidone—Myocardial infarction—Docetaxel—skin cancer	0.000196	0.000463	CcSEcCtD
Risperidone—Neuropathy peripheral—Docetaxel—skin cancer	0.000196	0.000463	CcSEcCtD
Risperidone—Dry mouth—Temozolomide—skin cancer	0.000195	0.000462	CcSEcCtD
Risperidone—Stomatitis—Docetaxel—skin cancer	0.000194	0.00046	CcSEcCtD
Risperidone—Jaundice—Docetaxel—skin cancer	0.000194	0.00046	CcSEcCtD
Risperidone—Pain—Bleomycin—skin cancer	0.000194	0.000459	CcSEcCtD
Risperidone—Conjunctivitis—Docetaxel—skin cancer	0.000194	0.000459	CcSEcCtD
Risperidone—Leukopenia—Fluorouracil—skin cancer	0.000193	0.000458	CcSEcCtD
Risperidone—Confusional state—Temozolomide—skin cancer	0.000193	0.000457	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000193	0.000456	CcSEcCtD
Risperidone—Anaphylactic shock—Temozolomide—skin cancer	0.000191	0.000453	CcSEcCtD
Risperidone—Oedema—Temozolomide—skin cancer	0.000191	0.000453	CcSEcCtD
Risperidone—Infection—Temozolomide—skin cancer	0.00019	0.00045	CcSEcCtD
Risperidone—Nausea—Imiquimod—skin cancer	0.00019	0.000449	CcSEcCtD
Risperidone—Hepatobiliary disease—Docetaxel—skin cancer	0.000189	0.000447	CcSEcCtD
Risperidone—Epistaxis—Docetaxel—skin cancer	0.000188	0.000446	CcSEcCtD
Risperidone—Nervous system disorder—Temozolomide—skin cancer	0.000188	0.000444	CcSEcCtD
Risperidone—Thrombocytopenia—Temozolomide—skin cancer	0.000187	0.000444	CcSEcCtD
Risperidone—Convulsion—Fluorouracil—skin cancer	0.000187	0.000443	CcSEcCtD
Risperidone—Feeling abnormal—Bleomycin—skin cancer	0.000187	0.000443	CcSEcCtD
Risperidone—Agranulocytosis—Docetaxel—skin cancer	0.000186	0.000441	CcSEcCtD
Risperidone—Skin disorder—Temozolomide—skin cancer	0.000186	0.00044	CcSEcCtD
Risperidone—Hyperhidrosis—Temozolomide—skin cancer	0.000185	0.000438	CcSEcCtD
Risperidone—Myalgia—Fluorouracil—skin cancer	0.000184	0.000435	CcSEcCtD
Risperidone—Chest pain—Fluorouracil—skin cancer	0.000184	0.000435	CcSEcCtD
Risperidone—Decreased appetite—Dactinomycin—skin cancer	0.000184	0.000435	CcSEcCtD
Risperidone—Fatigue—Dactinomycin—skin cancer	0.000182	0.000432	CcSEcCtD
Risperidone—Anorexia—Temozolomide—skin cancer	0.000182	0.000432	CcSEcCtD
Risperidone—Discomfort—Fluorouracil—skin cancer	0.000182	0.00043	CcSEcCtD
Risperidone—Pain—Dactinomycin—skin cancer	0.000181	0.000428	CcSEcCtD
Risperidone—Urticaria—Bleomycin—skin cancer	0.00018	0.000427	CcSEcCtD
Risperidone—Haemoglobin—Docetaxel—skin cancer	0.00018	0.000426	CcSEcCtD
Risperidone—Rhinitis—Docetaxel—skin cancer	0.00018	0.000425	CcSEcCtD
Risperidone—Body temperature increased—Bleomycin—skin cancer	0.000179	0.000425	CcSEcCtD
Risperidone—Hepatitis—Docetaxel—skin cancer	0.000179	0.000424	CcSEcCtD
Risperidone—Haemorrhage—Docetaxel—skin cancer	0.000179	0.000424	CcSEcCtD
Risperidone—Hypoaesthesia—Docetaxel—skin cancer	0.000178	0.000422	CcSEcCtD
Risperidone—Confusional state—Fluorouracil—skin cancer	0.000178	0.000421	CcSEcCtD
Risperidone—Pharyngitis—Docetaxel—skin cancer	0.000178	0.000421	CcSEcCtD
Risperidone—Urinary tract disorder—Docetaxel—skin cancer	0.000177	0.000419	CcSEcCtD
Risperidone—Oedema peripheral—Docetaxel—skin cancer	0.000176	0.000418	CcSEcCtD
Risperidone—Anaphylactic shock—Fluorouracil—skin cancer	0.000176	0.000417	CcSEcCtD
Risperidone—Oedema—Fluorouracil—skin cancer	0.000176	0.000417	CcSEcCtD
Risperidone—Connective tissue disorder—Docetaxel—skin cancer	0.000176	0.000417	CcSEcCtD
Risperidone—Urethral disorder—Docetaxel—skin cancer	0.000176	0.000416	CcSEcCtD
Risperidone—Infection—Fluorouracil—skin cancer	0.000175	0.000415	CcSEcCtD
Risperidone—Feeling abnormal—Dactinomycin—skin cancer	0.000174	0.000413	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000174	0.000413	CcSEcCtD
Risperidone—Insomnia—Temozolomide—skin cancer	0.000173	0.00041	CcSEcCtD
Risperidone—Gastrointestinal pain—Dactinomycin—skin cancer	0.000173	0.00041	CcSEcCtD
Risperidone—Nervous system disorder—Fluorouracil—skin cancer	0.000173	0.000409	CcSEcCtD
Risperidone—Thrombocytopenia—Fluorouracil—skin cancer	0.000173	0.000409	CcSEcCtD
Risperidone—Visual impairment—Docetaxel—skin cancer	0.000173	0.000409	CcSEcCtD
Risperidone—Tachycardia—Fluorouracil—skin cancer	0.000172	0.000407	CcSEcCtD
Risperidone—Paraesthesia—Temozolomide—skin cancer	0.000172	0.000407	CcSEcCtD
Risperidone—Dyspnoea—Temozolomide—skin cancer	0.000171	0.000404	CcSEcCtD
Risperidone—Somnolence—Temozolomide—skin cancer	0.00017	0.000403	CcSEcCtD
Risperidone—Erythema multiforme—Docetaxel—skin cancer	0.000169	0.000401	CcSEcCtD
Risperidone—Dyspepsia—Temozolomide—skin cancer	0.000168	0.000399	CcSEcCtD
Risperidone—Anorexia—Fluorouracil—skin cancer	0.000168	0.000398	CcSEcCtD
Risperidone—Eye disorder—Docetaxel—skin cancer	0.000167	0.000396	CcSEcCtD
Risperidone—Abdominal pain—Dactinomycin—skin cancer	0.000167	0.000396	CcSEcCtD
Risperidone—Body temperature increased—Dactinomycin—skin cancer	0.000167	0.000396	CcSEcCtD
Risperidone—Hypersensitivity—Bleomycin—skin cancer	0.000167	0.000396	CcSEcCtD
Risperidone—Decreased appetite—Temozolomide—skin cancer	0.000166	0.000394	CcSEcCtD
Risperidone—Cardiac disorder—Docetaxel—skin cancer	0.000166	0.000394	CcSEcCtD
Risperidone—Flushing—Docetaxel—skin cancer	0.000166	0.000394	CcSEcCtD
Risperidone—Gastrointestinal disorder—Temozolomide—skin cancer	0.000165	0.000391	CcSEcCtD
Risperidone—Fatigue—Temozolomide—skin cancer	0.000165	0.000391	CcSEcCtD
Risperidone—Hypotension—Fluorouracil—skin cancer	0.000165	0.00039	CcSEcCtD
Risperidone—Pain—Temozolomide—skin cancer	0.000164	0.000387	CcSEcCtD
Risperidone—Constipation—Temozolomide—skin cancer	0.000164	0.000387	CcSEcCtD
Risperidone—Asthenia—Bleomycin—skin cancer	0.000163	0.000385	CcSEcCtD
Risperidone—Angiopathy—Docetaxel—skin cancer	0.000163	0.000385	CcSEcCtD
Risperidone—Immune system disorder—Docetaxel—skin cancer	0.000162	0.000383	CcSEcCtD
Risperidone—Mediastinal disorder—Docetaxel—skin cancer	0.000161	0.000382	CcSEcCtD
Risperidone—Chills—Docetaxel—skin cancer	0.000161	0.000381	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000161	0.00038	CcSEcCtD
Risperidone—Pruritus—Bleomycin—skin cancer	0.000161	0.00038	CcSEcCtD
Risperidone—ABCB1—lymph node—skin cancer	0.00016	0.00187	CbGeAlD
Risperidone—Arrhythmia—Docetaxel—skin cancer	0.00016	0.000379	CcSEcCtD
Risperidone—Insomnia—Fluorouracil—skin cancer	0.000159	0.000378	CcSEcCtD
Risperidone—Paraesthesia—Fluorouracil—skin cancer	0.000158	0.000375	CcSEcCtD
Risperidone—Alopecia—Docetaxel—skin cancer	0.000158	0.000375	CcSEcCtD
Risperidone—Feeling abnormal—Temozolomide—skin cancer	0.000158	0.000373	CcSEcCtD
Risperidone—Dyspnoea—Fluorouracil—skin cancer	0.000157	0.000372	CcSEcCtD
Risperidone—Mental disorder—Docetaxel—skin cancer	0.000157	0.000372	CcSEcCtD
Risperidone—Somnolence—Fluorouracil—skin cancer	0.000157	0.000371	CcSEcCtD
Risperidone—Gastrointestinal pain—Temozolomide—skin cancer	0.000156	0.00037	CcSEcCtD
Risperidone—Erythema—Docetaxel—skin cancer	0.000156	0.000369	CcSEcCtD
Risperidone—Malnutrition—Docetaxel—skin cancer	0.000156	0.000369	CcSEcCtD
Risperidone—Hypersensitivity—Dactinomycin—skin cancer	0.000156	0.000369	CcSEcCtD
Risperidone—Dyspepsia—Fluorouracil—skin cancer	0.000155	0.000367	CcSEcCtD
Risperidone—Decreased appetite—Fluorouracil—skin cancer	0.000153	0.000363	CcSEcCtD
Risperidone—Dysgeusia—Docetaxel—skin cancer	0.000153	0.000362	CcSEcCtD
Risperidone—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000152	0.00036	CcSEcCtD
Risperidone—Urticaria—Temozolomide—skin cancer	0.000152	0.00036	CcSEcCtD
Risperidone—Asthenia—Dactinomycin—skin cancer	0.000152	0.000359	CcSEcCtD
Risperidone—Body temperature increased—Temozolomide—skin cancer	0.000151	0.000358	CcSEcCtD
Risperidone—Abdominal pain—Temozolomide—skin cancer	0.000151	0.000358	CcSEcCtD
Risperidone—Back pain—Docetaxel—skin cancer	0.000151	0.000357	CcSEcCtD
Risperidone—Pain—Fluorouracil—skin cancer	0.000151	0.000357	CcSEcCtD
Risperidone—Muscle spasms—Docetaxel—skin cancer	0.00015	0.000355	CcSEcCtD
Risperidone—Feeling abnormal—Fluorouracil—skin cancer	0.000145	0.000344	CcSEcCtD
Risperidone—Diarrhoea—Dactinomycin—skin cancer	0.000145	0.000343	CcSEcCtD
Risperidone—Vomiting—Bleomycin—skin cancer	0.000144	0.000341	CcSEcCtD
Risperidone—Anaemia—Docetaxel—skin cancer	0.000144	0.000341	CcSEcCtD
Risperidone—Rash—Bleomycin—skin cancer	0.000143	0.000339	CcSEcCtD
Risperidone—Dermatitis—Bleomycin—skin cancer	0.000143	0.000338	CcSEcCtD
Risperidone—Hypersensitivity—Temozolomide—skin cancer	0.000141	0.000334	CcSEcCtD
Risperidone—Urticaria—Fluorouracil—skin cancer	0.00014	0.000332	CcSEcCtD
Risperidone—Syncope—Docetaxel—skin cancer	0.00014	0.000331	CcSEcCtD
Risperidone—Leukopenia—Docetaxel—skin cancer	0.00014	0.00033	CcSEcCtD
Risperidone—Body temperature increased—Fluorouracil—skin cancer	0.000139	0.00033	CcSEcCtD
Risperidone—Palpitations—Docetaxel—skin cancer	0.000138	0.000326	CcSEcCtD
Risperidone—Asthenia—Temozolomide—skin cancer	0.000137	0.000325	CcSEcCtD
Risperidone—Loss of consciousness—Docetaxel—skin cancer	0.000137	0.000324	CcSEcCtD
Risperidone—Cough—Docetaxel—skin cancer	0.000136	0.000322	CcSEcCtD
Risperidone—Pruritus—Temozolomide—skin cancer	0.000135	0.000321	CcSEcCtD
Risperidone—Convulsion—Docetaxel—skin cancer	0.000135	0.00032	CcSEcCtD
Risperidone—Nausea—Bleomycin—skin cancer	0.000135	0.000319	CcSEcCtD
Risperidone—Hypertension—Docetaxel—skin cancer	0.000135	0.000319	CcSEcCtD
Risperidone—Vomiting—Dactinomycin—skin cancer	0.000135	0.000318	CcSEcCtD
Risperidone—Rash—Dactinomycin—skin cancer	0.000133	0.000316	CcSEcCtD
Risperidone—Myalgia—Docetaxel—skin cancer	0.000133	0.000314	CcSEcCtD
Risperidone—Chest pain—Docetaxel—skin cancer	0.000133	0.000314	CcSEcCtD
Risperidone—Arthralgia—Docetaxel—skin cancer	0.000133	0.000314	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000132	0.000312	CcSEcCtD
Risperidone—Diarrhoea—Temozolomide—skin cancer	0.000131	0.00031	CcSEcCtD
Risperidone—Hypersensitivity—Fluorouracil—skin cancer	0.00013	0.000308	CcSEcCtD
Risperidone—Dry mouth—Docetaxel—skin cancer	0.00013	0.000307	CcSEcCtD
Risperidone—Confusional state—Docetaxel—skin cancer	0.000128	0.000304	CcSEcCtD
Risperidone—Oedema—Docetaxel—skin cancer	0.000127	0.000301	CcSEcCtD
Risperidone—Anaphylactic shock—Docetaxel—skin cancer	0.000127	0.000301	CcSEcCtD
Risperidone—Dizziness—Temozolomide—skin cancer	0.000127	0.0003	CcSEcCtD
Risperidone—Infection—Docetaxel—skin cancer	0.000126	0.000299	CcSEcCtD
Risperidone—Nausea—Dactinomycin—skin cancer	0.000126	0.000298	CcSEcCtD
Risperidone—Shock—Docetaxel—skin cancer	0.000125	0.000296	CcSEcCtD
Risperidone—Nervous system disorder—Docetaxel—skin cancer	0.000125	0.000295	CcSEcCtD
Risperidone—Pruritus—Fluorouracil—skin cancer	0.000125	0.000295	CcSEcCtD
Risperidone—Thrombocytopenia—Docetaxel—skin cancer	0.000125	0.000295	CcSEcCtD
Risperidone—Tachycardia—Docetaxel—skin cancer	0.000124	0.000294	CcSEcCtD
Risperidone—Skin disorder—Docetaxel—skin cancer	0.000124	0.000293	CcSEcCtD
Risperidone—Vomiting—Temozolomide—skin cancer	0.000122	0.000288	CcSEcCtD
Risperidone—Anorexia—Docetaxel—skin cancer	0.000121	0.000287	CcSEcCtD
Risperidone—Rash—Temozolomide—skin cancer	0.000121	0.000286	CcSEcCtD
Risperidone—Diarrhoea—Fluorouracil—skin cancer	0.000121	0.000286	CcSEcCtD
Risperidone—Dermatitis—Temozolomide—skin cancer	0.000121	0.000285	CcSEcCtD
Risperidone—Headache—Temozolomide—skin cancer	0.00012	0.000284	CcSEcCtD
Risperidone—Hypotension—Docetaxel—skin cancer	0.000119	0.000282	CcSEcCtD
Risperidone—Dizziness—Fluorouracil—skin cancer	0.000117	0.000276	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000116	0.000274	CcSEcCtD
Risperidone—Insomnia—Docetaxel—skin cancer	0.000115	0.000273	CcSEcCtD
Risperidone—Paraesthesia—Docetaxel—skin cancer	0.000114	0.000271	CcSEcCtD
Risperidone—Nausea—Temozolomide—skin cancer	0.000114	0.000269	CcSEcCtD
Risperidone—Dyspnoea—Docetaxel—skin cancer	0.000113	0.000269	CcSEcCtD
Risperidone—Somnolence—Docetaxel—skin cancer	0.000113	0.000268	CcSEcCtD
Risperidone—Vomiting—Fluorouracil—skin cancer	0.000112	0.000265	CcSEcCtD
Risperidone—Dyspepsia—Docetaxel—skin cancer	0.000112	0.000265	CcSEcCtD
Risperidone—Rash—Fluorouracil—skin cancer	0.000111	0.000263	CcSEcCtD
Risperidone—Dermatitis—Fluorouracil—skin cancer	0.000111	0.000263	CcSEcCtD
Risperidone—Decreased appetite—Docetaxel—skin cancer	0.000111	0.000262	CcSEcCtD
Risperidone—Headache—Fluorouracil—skin cancer	0.00011	0.000262	CcSEcCtD
Risperidone—Gastrointestinal disorder—Docetaxel—skin cancer	0.00011	0.00026	CcSEcCtD
Risperidone—Fatigue—Docetaxel—skin cancer	0.00011	0.00026	CcSEcCtD
Risperidone—Pain—Docetaxel—skin cancer	0.000109	0.000258	CcSEcCtD
Risperidone—Constipation—Docetaxel—skin cancer	0.000109	0.000258	CcSEcCtD
Risperidone—Feeling abnormal—Docetaxel—skin cancer	0.000105	0.000248	CcSEcCtD
Risperidone—Nausea—Fluorouracil—skin cancer	0.000105	0.000248	CcSEcCtD
Risperidone—Gastrointestinal pain—Docetaxel—skin cancer	0.000104	0.000246	CcSEcCtD
Risperidone—Abdominal pain—Docetaxel—skin cancer	0.000101	0.000238	CcSEcCtD
Risperidone—Body temperature increased—Docetaxel—skin cancer	0.000101	0.000238	CcSEcCtD
Risperidone—Hypersensitivity—Docetaxel—skin cancer	9.38e-05	0.000222	CcSEcCtD
Risperidone—Asthenia—Docetaxel—skin cancer	9.13e-05	0.000216	CcSEcCtD
Risperidone—Pruritus—Docetaxel—skin cancer	9e-05	0.000213	CcSEcCtD
Risperidone—Diarrhoea—Docetaxel—skin cancer	8.71e-05	0.000206	CcSEcCtD
Risperidone—Dizziness—Docetaxel—skin cancer	8.42e-05	0.000199	CcSEcCtD
Risperidone—Vomiting—Docetaxel—skin cancer	8.09e-05	0.000192	CcSEcCtD
Risperidone—Rash—Docetaxel—skin cancer	8.02e-05	0.00019	CcSEcCtD
Risperidone—Dermatitis—Docetaxel—skin cancer	8.02e-05	0.00019	CcSEcCtD
Risperidone—Headache—Docetaxel—skin cancer	7.97e-05	0.000189	CcSEcCtD
Risperidone—Nausea—Docetaxel—skin cancer	7.56e-05	0.000179	CcSEcCtD
Risperidone—HRH1—Signaling Pathways—RASA1—skin cancer	1.53e-05	0.000427	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—SHH—skin cancer	1.51e-05	0.000421	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—FOXO4—skin cancer	1.5e-05	0.000421	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—RASA1—skin cancer	1.5e-05	0.000419	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PTCH1—skin cancer	1.48e-05	0.000414	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—SMO—skin cancer	1.48e-05	0.000414	CbGpPWpGaD
Risperidone—ADRA2B—Hemostasis—NRAS—skin cancer	1.48e-05	0.000412	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—SMO—skin cancer	1.46e-05	0.000408	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PTCH1—skin cancer	1.46e-05	0.000408	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PTCH1—skin cancer	1.46e-05	0.000407	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—SMO—skin cancer	1.46e-05	0.000407	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—FOXO4—skin cancer	1.45e-05	0.000406	CbGpPWpGaD
Risperidone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.45e-05	0.000406	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—FOXO4—skin cancer	1.44e-05	0.000404	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PTGER4—skin cancer	1.44e-05	0.000403	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PTCH1—skin cancer	1.43e-05	0.000399	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—SMO—skin cancer	1.43e-05	0.000399	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PTGER4—skin cancer	1.42e-05	0.000397	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PTGER4—skin cancer	1.42e-05	0.000396	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—FOXO4—skin cancer	1.41e-05	0.000393	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—SHH—skin cancer	1.4e-05	0.000391	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—RASA1—skin cancer	1.39e-05	0.000389	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PTGER4—skin cancer	1.39e-05	0.000389	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—FOXO4—skin cancer	1.38e-05	0.000387	CbGpPWpGaD
Risperidone—ADRA2C—Hemostasis—NRAS—skin cancer	1.38e-05	0.000385	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PTCH1—skin cancer	1.33e-05	0.000371	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—SMO—skin cancer	1.33e-05	0.000371	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—TERT—skin cancer	1.31e-05	0.000366	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PLIN2—skin cancer	1.3e-05	0.000364	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—TERT—skin cancer	1.3e-05	0.000363	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PTGER4—skin cancer	1.29e-05	0.000361	CbGpPWpGaD
Risperidone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.29e-05	0.000361	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—FOXO4—skin cancer	1.28e-05	0.000356	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—TERT—skin cancer	1.27e-05	0.000356	CbGpPWpGaD
Risperidone—ADRA2B—Hemostasis—KRAS—skin cancer	1.27e-05	0.000355	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—FOXO4—skin cancer	1.25e-05	0.000351	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—TERT—skin cancer	1.25e-05	0.00035	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—FOXO4—skin cancer	1.25e-05	0.00035	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—ERCC2—skin cancer	1.23e-05	0.000345	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—FOXO4—skin cancer	1.23e-05	0.000343	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—ERCC2—skin cancer	1.2e-05	0.000335	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—TERT—skin cancer	1.2e-05	0.000334	CbGpPWpGaD
Risperidone—ADRA2C—Hemostasis—KRAS—skin cancer	1.19e-05	0.000332	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—ENO2—skin cancer	1.16e-05	0.000324	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—FOXO4—skin cancer	1.14e-05	0.000319	CbGpPWpGaD
Risperidone—ADRA2B—Hemostasis—TP53—skin cancer	1.13e-05	0.000315	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TERT—skin cancer	1.13e-05	0.000315	CbGpPWpGaD
Risperidone—ADRA2A—Hemostasis—NRAS—skin cancer	1.12e-05	0.000313	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TERT—skin cancer	1.11e-05	0.000311	CbGpPWpGaD
Risperidone—HTR7—Signaling by GPCR—NRAS—skin cancer	1.1e-05	0.000308	CbGpPWpGaD
Risperidone—HTR1D—Signaling by GPCR—NRAS—skin cancer	1.1e-05	0.000306	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—ENO2—skin cancer	1.09e-05	0.000305	CbGpPWpGaD
Risperidone—ADRA2B—Hemostasis—HRAS—skin cancer	1.08e-05	0.000302	CbGpPWpGaD
Risperidone—HTR1B—Signaling by GPCR—NRAS—skin cancer	1.07e-05	0.0003	CbGpPWpGaD
Risperidone—DRD4—Signaling by GPCR—NRAS—skin cancer	1.06e-05	0.000295	CbGpPWpGaD
Risperidone—ADRA2C—Hemostasis—TP53—skin cancer	1.05e-05	0.000295	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CSPG4—skin cancer	1.05e-05	0.000293	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—BRAF—skin cancer	1.04e-05	0.00029	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—BRAF—skin cancer	1.03e-05	0.000288	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—BRAF—skin cancer	1.01e-05	0.000282	CbGpPWpGaD
Risperidone—ADRA2C—Hemostasis—HRAS—skin cancer	1.01e-05	0.000282	CbGpPWpGaD
Risperidone—HTR2B—Signaling by GPCR—NRAS—skin cancer	1.01e-05	0.000282	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TERT—skin cancer	1e-05	0.000281	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—BRAF—skin cancer	9.92e-06	0.000277	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—ERCC2—skin cancer	9.73e-06	0.000272	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TERT—skin cancer	9.7e-06	0.000271	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TERT—skin cancer	9.65e-06	0.00027	CbGpPWpGaD
Risperidone—ADRA2A—Hemostasis—KRAS—skin cancer	9.63e-06	0.000269	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—NRAS—skin cancer	9.5e-06	0.000266	CbGpPWpGaD
Risperidone—HTR7—Signaling by GPCR—KRAS—skin cancer	9.49e-06	0.000265	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—BRAF—skin cancer	9.47e-06	0.000265	CbGpPWpGaD
Risperidone—HTR1D—Signaling by GPCR—KRAS—skin cancer	9.43e-06	0.000264	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TERT—skin cancer	9.39e-06	0.000262	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—NRAS—skin cancer	9.38e-06	0.000262	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TERT—skin cancer	9.24e-06	0.000258	CbGpPWpGaD
Risperidone—HTR1B—Signaling by GPCR—KRAS—skin cancer	9.23e-06	0.000258	CbGpPWpGaD
Risperidone—DRD4—Signaling by GPCR—KRAS—skin cancer	9.09e-06	0.000254	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—BRAF—skin cancer	8.93e-06	0.00025	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—ERCC2—skin cancer	8.91e-06	0.000249	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—BRAF—skin cancer	8.81e-06	0.000246	CbGpPWpGaD
Risperidone—HTR2B—Signaling by GPCR—KRAS—skin cancer	8.67e-06	0.000242	CbGpPWpGaD
Risperidone—ADRA2A—Hemostasis—TP53—skin cancer	8.56e-06	0.000239	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TERT—skin cancer	8.52e-06	0.000238	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—NRAS—skin cancer	8.47e-06	0.000237	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TERT—skin cancer	8.38e-06	0.000234	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TERT—skin cancer	8.36e-06	0.000234	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TERT—skin cancer	8.21e-06	0.000229	CbGpPWpGaD
Risperidone—ADRA2A—Hemostasis—HRAS—skin cancer	8.19e-06	0.000229	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—KRAS—skin cancer	8.18e-06	0.000229	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—NRAS—skin cancer	8.17e-06	0.000228	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—NRAS—skin cancer	8.13e-06	0.000227	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—KRAS—skin cancer	8.07e-06	0.000226	CbGpPWpGaD
Risperidone—HTR7—Signaling by GPCR—HRAS—skin cancer	8.07e-06	0.000226	CbGpPWpGaD
Risperidone—HTR1D—Signaling by GPCR—HRAS—skin cancer	8.02e-06	0.000224	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—BRAF—skin cancer	7.96e-06	0.000222	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—NRAS—skin cancer	7.91e-06	0.000221	CbGpPWpGaD
Risperidone—HTR1B—Signaling by GPCR—HRAS—skin cancer	7.85e-06	0.000219	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—NRAS—skin cancer	7.78e-06	0.000218	CbGpPWpGaD
Risperidone—DRD4—Signaling by GPCR—HRAS—skin cancer	7.72e-06	0.000216	CbGpPWpGaD
Risperidone—HTR7—Signaling by GPCR—IL6—skin cancer	7.72e-06	0.000216	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—BRAF—skin cancer	7.68e-06	0.000215	CbGpPWpGaD
Risperidone—HTR1D—Signaling by GPCR—IL6—skin cancer	7.67e-06	0.000214	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—BRAF—skin cancer	7.64e-06	0.000214	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TERT—skin cancer	7.62e-06	0.000213	CbGpPWpGaD
Risperidone—HTR1B—Signaling by GPCR—IL6—skin cancer	7.51e-06	0.00021	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—BRAF—skin cancer	7.43e-06	0.000208	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—PTGS2—skin cancer	7.39e-06	0.000207	CbGpPWpGaD
Risperidone—DRD4—Signaling by GPCR—IL6—skin cancer	7.39e-06	0.000207	CbGpPWpGaD
Risperidone—HTR2B—Signaling by GPCR—HRAS—skin cancer	7.37e-06	0.000206	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—BRAF—skin cancer	7.32e-06	0.000204	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—KRAS—skin cancer	7.29e-06	0.000204	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—PTGS2—skin cancer	7.18e-06	0.000201	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—NRAS—skin cancer	7.18e-06	0.000201	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ENO2—skin cancer	7.13e-06	0.000199	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—NRAS—skin cancer	7.06e-06	0.000197	CbGpPWpGaD
Risperidone—HTR2B—Signaling by GPCR—IL6—skin cancer	7.06e-06	0.000197	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—NRAS—skin cancer	7.05e-06	0.000197	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—KRAS—skin cancer	7.03e-06	0.000197	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—KRAS—skin cancer	7e-06	0.000196	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—HRAS—skin cancer	6.95e-06	0.000194	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—NRAS—skin cancer	6.91e-06	0.000193	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—HRAS—skin cancer	6.86e-06	0.000192	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—KRAS—skin cancer	6.81e-06	0.00019	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—BRAF—skin cancer	6.74e-06	0.000189	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—ERCC2—skin cancer	6.73e-06	0.000188	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—KRAS—skin cancer	6.7e-06	0.000187	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—IL6—skin cancer	6.65e-06	0.000186	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—BRAF—skin cancer	6.64e-06	0.000186	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—BRAF—skin cancer	6.62e-06	0.000185	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—IL6—skin cancer	6.57e-06	0.000184	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—NRAS—skin cancer	6.51e-06	0.000182	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—BRAF—skin cancer	6.5e-06	0.000182	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—NRAS—skin cancer	6.47e-06	0.000181	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—NRAS—skin cancer	6.42e-06	0.00018	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—ERCC2—skin cancer	6.34e-06	0.000177	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—NRAS—skin cancer	6.34e-06	0.000177	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—NRAS—skin cancer	6.24e-06	0.000174	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—HRAS—skin cancer	6.19e-06	0.000173	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—KRAS—skin cancer	6.18e-06	0.000173	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—KRAS—skin cancer	6.08e-06	0.00017	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—KRAS—skin cancer	6.06e-06	0.000169	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—BRAF—skin cancer	6.04e-06	0.000169	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—HRAS—skin cancer	5.98e-06	0.000167	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—NRAS—skin cancer	5.95e-06	0.000166	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—KRAS—skin cancer	5.95e-06	0.000166	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—HRAS—skin cancer	5.95e-06	0.000166	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—IL6—skin cancer	5.93e-06	0.000166	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PTGS2—skin cancer	5.83e-06	0.000163	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—HRAS—skin cancer	5.79e-06	0.000162	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—IL6—skin cancer	5.72e-06	0.00016	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—HRAS—skin cancer	5.69e-06	0.000159	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—IL6—skin cancer	5.69e-06	0.000159	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—NRAS—skin cancer	5.61e-06	0.000157	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—KRAS—skin cancer	5.61e-06	0.000157	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—KRAS—skin cancer	5.57e-06	0.000156	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—NRAS—skin cancer	5.54e-06	0.000155	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—IL6—skin cancer	5.54e-06	0.000155	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—KRAS—skin cancer	5.53e-06	0.000155	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—KRAS—skin cancer	5.45e-06	0.000152	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—IL6—skin cancer	5.45e-06	0.000152	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—KRAS—skin cancer	5.37e-06	0.00015	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTGS2—skin cancer	5.34e-06	0.000149	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—HRAS—skin cancer	5.25e-06	0.000147	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—HRAS—skin cancer	5.17e-06	0.000144	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—HRAS—skin cancer	5.15e-06	0.000144	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—KRAS—skin cancer	5.12e-06	0.000143	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—HRAS—skin cancer	5.06e-06	0.000141	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—IL6—skin cancer	5.02e-06	0.00014	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—NRAS—skin cancer	5e-06	0.00014	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—TP53—skin cancer	4.98e-06	0.000139	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—TP53—skin cancer	4.95e-06	0.000138	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—IL6—skin cancer	4.94e-06	0.000138	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—IL6—skin cancer	4.93e-06	0.000138	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—TP53—skin cancer	4.85e-06	0.000136	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—IL6—skin cancer	4.84e-06	0.000135	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—KRAS—skin cancer	4.83e-06	0.000135	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—NRAS—skin cancer	4.83e-06	0.000135	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—NRAS—skin cancer	4.8e-06	0.000134	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—TP53—skin cancer	4.77e-06	0.000133	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—KRAS—skin cancer	4.77e-06	0.000133	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—HRAS—skin cancer	4.77e-06	0.000133	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—HRAS—skin cancer	4.74e-06	0.000132	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—HRAS—skin cancer	4.7e-06	0.000131	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—NRAS—skin cancer	4.67e-06	0.000131	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—HRAS—skin cancer	4.64e-06	0.00013	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—NRAS—skin cancer	4.6e-06	0.000129	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—HRAS—skin cancer	4.56e-06	0.000128	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—IL6—skin cancer	4.56e-06	0.000128	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—TP53—skin cancer	4.55e-06	0.000127	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—IL6—skin cancer	4.53e-06	0.000127	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—IL6—skin cancer	4.5e-06	0.000126	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—IL6—skin cancer	4.44e-06	0.000124	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—IL6—skin cancer	4.37e-06	0.000122	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—HRAS—skin cancer	4.36e-06	0.000122	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—KRAS—skin cancer	4.3e-06	0.00012	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TP53—skin cancer	4.29e-06	0.00012	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NRAS—skin cancer	4.24e-06	0.000118	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TP53—skin cancer	4.24e-06	0.000118	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NRAS—skin cancer	4.17e-06	0.000117	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—IL6—skin cancer	4.17e-06	0.000117	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NRAS—skin cancer	4.16e-06	0.000116	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—KRAS—skin cancer	4.16e-06	0.000116	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ERCC2—skin cancer	4.14e-06	0.000116	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—KRAS—skin cancer	4.13e-06	0.000116	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—HRAS—skin cancer	4.11e-06	0.000115	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NRAS—skin cancer	4.08e-06	0.000114	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—HRAS—skin cancer	4.05e-06	0.000113	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTGS2—skin cancer	4.03e-06	0.000113	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—KRAS—skin cancer	4.02e-06	0.000112	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—KRAS—skin cancer	3.96e-06	0.000111	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—IL6—skin cancer	3.93e-06	0.00011	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—IL6—skin cancer	3.88e-06	0.000108	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TP53—skin cancer	3.83e-06	0.000107	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTGS2—skin cancer	3.8e-06	0.000106	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NRAS—skin cancer	3.79e-06	0.000106	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TP53—skin cancer	3.69e-06	0.000103	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TP53—skin cancer	3.67e-06	0.000103	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—HRAS—skin cancer	3.66e-06	0.000102	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—KRAS—skin cancer	3.65e-06	0.000102	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—KRAS—skin cancer	3.59e-06	0.0001	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—KRAS—skin cancer	3.58e-06	0.0001	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TP53—skin cancer	3.57e-06	9.99e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—HRAS—skin cancer	3.53e-06	9.87e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TP53—skin cancer	3.52e-06	9.83e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—KRAS—skin cancer	3.51e-06	9.82e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—HRAS—skin cancer	3.51e-06	9.82e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IL6—skin cancer	3.5e-06	9.79e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—HRAS—skin cancer	3.42e-06	9.55e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IL6—skin cancer	3.38e-06	9.45e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—HRAS—skin cancer	3.36e-06	9.4e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IL6—skin cancer	3.36e-06	9.4e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IL6—skin cancer	3.27e-06	9.14e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—KRAS—skin cancer	3.27e-06	9.13e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TP53—skin cancer	3.24e-06	9.06e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IL6—skin cancer	3.22e-06	9e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TP53—skin cancer	3.19e-06	8.92e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TP53—skin cancer	3.18e-06	8.9e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TP53—skin cancer	3.12e-06	8.73e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—HRAS—skin cancer	3.1e-06	8.67e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—HRAS—skin cancer	3.05e-06	8.53e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—HRAS—skin cancer	3.04e-06	8.51e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—HRAS—skin cancer	2.99e-06	8.35e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL6—skin cancer	2.97e-06	8.3e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL6—skin cancer	2.92e-06	8.16e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL6—skin cancer	2.91e-06	8.15e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TP53—skin cancer	2.9e-06	8.11e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL6—skin cancer	2.86e-06	7.99e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—HRAS—skin cancer	2.78e-06	7.76e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL6—skin cancer	2.66e-06	7.43e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTGS2—skin cancer	2.48e-06	6.95e-05	CbGpPWpGaD
